1. Allow the lyophilized vial to reach room temperature before opening to minimize moisture condensation.
2. Draw 3 mL bacteriostatic water (0.9% benzyl alcohol) with a sterile syringe.
3. Inject slowly down the vial wall to avoid foaming; do not aim directly at the powder.
4. Gently swirl until the powder fully dissolves (do not shake vigorously). Solution should be clear and colorless.
5. Label with the reconstitution date and refrigerate at 2 to 8 °C, protected from light.
6. Use within 14 days; inspect before each use for clarity. Discard if discoloration or precipitate appears. At 166.67 mg/mL, 1 unit = 0.01 mL = 1.67 mg on a U-100 insulin syringe. 50 mg = 30 units; 75 mg = 45 units; 100 mg = 60 unit

NAD+ is a coenzyme central to redox reactions, energy metabolism (glycolysis, TCA cycle, oxidative phosphorylation), and cellular maintenance pathways including DNA repair and mitochondrial biogenesis. Cellular NAD+ levels decline with age and metabolic stress, which may contribute to reduced mitochondrial function and impaired cellular resilience. Clinical research on NAD+ therapy has primarily used intravenous infusions at high doses (500 to 1,000 mg) for applications such as addiction treatment and acute metabolic support. A pilot metabolic study demonstrated that a 750 mg NAD+ IV infusion over 6 hours was well-tolerated in humans, with rapid metabolic clearance and no acute toxicity. Subcutaneous (SC) or intramuscular (IM) injections at lower doses (tens to low hundreds of milligrams) are emerging as practical alternatives for maintenance therapy. Conservative protocols start around 50 to 100 mg per injection a few times per week; the present protocol uses daily SC administration with gradual titration to optimize individual tolerance.

• May support cellular energy production and mitochondrial function through replenishment of NAD+ pools.
• Human case reports and pilot studies suggest benefits at 100 to 300 mg/day ranges for cognitive support
  and metabolic health.
• High-dose IV protocols (500 to 1,500 mg daily for ~10 days) have been used in open-label studies for
  substance use disorder, with reports of reduced cravings and improved mood in follow-ups.
• No severe adverse events have been reported in published NAD+/NADH trials; side effects are generally
  mild.
• Potential side effects: high doses can produce adverse reactions such as insomnia, anxiety, or fatigue
• if escalated too quickly; gradual titration is advised.
• Mild injection-site reactions (redness, itching, soreness) may occur with subcutaneous administration;
  typically resolve with site rotation.
• Some individuals report transient headache or flushing; these effects are generally dose-dependent.
• Doses exceeding ~200 to 300 mg/day should generally be reserved for supervised therapeutic use.